WallStreetZenWallStreetZen

NASDAQ: DOMH
Dominari Holdings Inc Stock

$1.86+0.00 (+0%)
Updated Jul 17, 2024
DOMH Price
$1.86
Fair Value Price
-$0.20
Market Cap
$11.15M
52 Week Low
$1.76
52 Week High
$3.40
P/E
-0.4x
P/B
0.23x
P/S
4.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.41M
Earnings
-$24.56M
Gross Margin
100%
Operating Margin
-721.11%
Profit Margin
-721.1%
Debt to Equity
0.1
Operating Cash Flow
-$27M
Beta
-0.04
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

DOMH Overview

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DOMH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DOMH ($1.86) is overvalued by 1,029.68% relative to our estimate of its Fair Value price of -$0.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DOMH ($1.86) is not significantly undervalued (1,029.68%) relative to our estimate of its Fair Value price of -$0.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DOMH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DOMH due diligence checks available for Premium users.

Be the first to know about important DOMH news, forecast changes, insider trades & much more!

Valuation

DOMH fair value

Fair Value of DOMH stock based on Discounted Cash Flow (DCF)
Price
$1.86
Fair Value
-$0.20
Undervalued by
1,029.68%
DOMH ($1.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DOMH ($1.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DOMH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DOMH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.4x
Industry
-21.17x
Market
30.24x

DOMH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.23x
Industry
6.35x
DOMH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DOMH's financial health

Profit margin

Revenue
$1.4M
Net Income
-$5.4M
Profit Margin
-398%
DOMH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DOMH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$52.2M
Liabilities
$4.5M
Debt to equity
0.1
DOMH's short-term assets ($25.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DOMH's short-term assets ($25.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DOMH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DOMH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.6M
Investing
$7.7M
Financing
$0.0
DOMH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DOMH vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DOMH$11.15M0.00%-0.40x0.23x
EVAX$10.95M-7.96%-0.36x-2.32x
TRAW$11.36M+6.90%-0.52x1.89x
ERNA$10.93M-2.88%-0.48x-3.20x
BRTX$11.37M-4.00%-1.24x0.78x

Dominari Holdings Stock FAQ

What is Dominari Holdings's quote symbol?

(NASDAQ: DOMH) Dominari Holdings trades on the NASDAQ under the ticker symbol DOMH. Dominari Holdings stock quotes can also be displayed as NASDAQ: DOMH.

If you're new to stock investing, here's how to buy Dominari Holdings stock.

What is the 52 week high and low for Dominari Holdings (NASDAQ: DOMH)?

(NASDAQ: DOMH) Dominari Holdings's 52-week high was $3.40, and its 52-week low was $1.76. It is currently -45.29% from its 52-week high and 5.68% from its 52-week low.

How much is Dominari Holdings stock worth today?

(NASDAQ: DOMH) Dominari Holdings currently has 5,995,065 outstanding shares. With Dominari Holdings stock trading at $1.86 per share, the total value of Dominari Holdings stock (market capitalization) is $11.15M.

Dominari Holdings stock was originally listed at a price of $1,355,728.58 in Dec 31, 1997. If you had invested in Dominari Holdings stock at $1,355,728.58, your return over the last 26 years would have been -100%, for an annualized return of -40.5% (not including any dividends or dividend reinvestments).

How much is Dominari Holdings's stock price per share?

(NASDAQ: DOMH) Dominari Holdings stock price per share is $1.86 today (as of Jul 17, 2024).

What is Dominari Holdings's Market Cap?

(NASDAQ: DOMH) Dominari Holdings's market cap is $11.15M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Dominari Holdings's market cap is calculated by multiplying DOMH's current stock price of $1.86 by DOMH's total outstanding shares of 5,995,065.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.